Prostate cancer remains a significant global public health concern, including in Nigeria, where increasing incidence and late- stage presentation have been reported in urban centres such as Port Harcourt. This study compared prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) levels among male smokers and non-smokers in Port Harcourt, Nigeria, to assess their diagnostic relevance and the influence of lifestyle factors. A comparative cross-sectional design was employed, involving 180 male participants aged 40–60 years: 90 smokers and 90 non-smokers recruited through convenience sampling. Data were collected using structured questionnaires covering demographic and lifestyle variables. We collected, processed, and analysed venous blood samples (5 mL) for PSA and PSMA levels using sandwich enzyme-linked immunosorbent assay (ELISA) techniques. Statistical analyses were performed using GraphPad Prism version 8.02. We compared groups using one-way ANOVA and post hoc tests, with statistical significance set at p < 0.05. We also performed receiver operating characteristic (ROC) curve analysis to evaluate diagnostic performance. The results showed that smokers had significantly higher mean PSA (4.48 ± 1.082 ng/mL) and PSMA (4.00 ± 1.628 ng/mL) levels than non- smokers (PSA: 1.98 ± 0.298 ng/mL; PSMA: 1.88 ± 0.145 ng/mL), with p- values of 0.0003 and < 0.0001, respectively. ROC analysis showed that PSMA had superior diagnostic performance (AUC = 0.766) than PSA (AUC = 0.634). Alcohol consumption was also significantly associated with elevated PSA and PSMA levels, whereas exercise had a significant but variable effect. Age influenced biomarker levels in specific groups, while smoking intensity and duration showed weak, non- significant correlations with both markers. In conclusion, smoking was associated with elevated prostate biomarkers, suggesting an increased risk of prostate dysfunction. PSMA showed greater diagnostic capability than PSA, suggesting it may be a more reliable biomarker for early detection. Integrating both biomarkers with lifestyle interventions may strengthen prostate cancer screening and prevention strategies.
| Published in | International Journal of Clinical and Experimental Medical Sciences (Volume 12, Issue 5) |
| DOI | 10.11648/j.ijcems.20261205.12 |
| Page(s) | 96-102 |
| Creative Commons |
This is an Open Access article, distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution and reproduction in any medium or format, provided the original work is properly cited. |
| Copyright |
Copyright © The Author(s), 2026. Published by Science Publishing Group |
PSA, PSMA, Prostate, Cigarettes, Smokers
Groups | Number of Subjects | |
|---|---|---|
Total Subjects | 180 | |
Non-Smokers (Control) | 90 (50%) | |
Smokers (Test) | 90 (50%) | |
Non-Alcohol Users | 35 (38.9%) | |
Alcohol Users | 55 (61.1%) | |
Age Grouping | Smokers | Non-Smokers |
40 - 44 Years | 40 (44.4%) | 35 (38.9%) |
45 - 49 Years | 16 (17.8%) | 24 (26.7%) |
50 - 54 Years | 15 (16.7%) | 16 (17.8%) |
55 - 59 Years | 14 (15.6%) | 9 (10.0%) |
60 - 64 Years | 5 (5.5%) 90 (100%) | 6 (6.6%) 90 (100%) |
Physical Activity | ||
No Exercise | 32 (35.6%) | |
Exercise | 58 (64.4%) | |
Parameter/Groups | PSA (ng/ml) | PSMA (ng/ml) |
|---|---|---|
Control (N = 90) | 1.98 ± 0.298 | 1.88 ± 0.145 |
Test (N = 90) | 4.48 ± 1.082 | 4.00 ± 1.628 |
P-value | 0.0003 | <0.0001 |
Remark | S | S |
Area under the ROC curve | PSA | PSMA |
|---|---|---|
Area | 0.634 | 0.766 |
Std. Error | 0.044 | 0.0373 |
P value | 0.0018 | <0.0001 |
PSA | Prostate-specific Antigen |
PSMA | Prostate-specific Membrane Antigen |
ELISA | Enzyme-linked Immunosorbent Assay |
ROC | Receiver Operating Characteristic |
AUC | Area Under the Curve |
TMB | Tetramethylbenzidine |
HRP | Horseradish Peroxidase |
PSMA-PET | Prostate-Specific Membrane Antigen–Positron Emission Tomography |
| [1] | Tolani, M. A., Agbo, C. A., Paciorek, A., Umar, S. S., & Ojewola, R. W. (2024). Detection and management of localised prostate cancer in Nigeria: Barriers and facilitators according to patients, caregivers and healthcare providers. BMC Health Services Research, 24, 918. |
| [2] | Parsi, M. A., Jones, J. S., & Klein, E. A. (2021). Prostate-specific antigen and newer biomarkers in prostate cancer screening and diagnosis. Urologic Clinics of North America, 48(1), 1–12. |
| [3] | Al Saffar, H., Mari, A., & Tayara, M. (2024). Emerging role of prostate-specific membrane antigen in early prostate cancer diagnosis and risk stratification. Cancers, 16(4), 912. |
| [4] | Bouchelouche, K., Choyke, P. L., & Capala, J. (2018). Prostate-specific membrane antigen as a target for imaging and therapy. American Journal of Nuclear Medicine and Molecular Imaging, 8(3), 220–234. |
| [5] | Burden, E., Issues, I., & Prospects, P. (2023). Burden, issues and prospects of prostate cancer in Nigeria. African Journal of Urology, 29(1), 44–52. |
| [6] | Olorunniyi, S. B., & Ogo, C. N. (2025). Predictors of late diagnosis of prostate cancer among men of African ancestry receiving care at a urology clinic in Nigeria. ecancermedicalscience, 19, 1917. |
| [7] | Harmatz, E. S., Goldberg, H., Del Giudice, F., & Zlotta, A. R. (2024). Biomarker comparison and screening strategies in prostate cancer diagnosis. European Urology Oncology, 7(1), 11–20. |
| [8] | Adeloye, D., David, R. A., Aderemi, A. V., Iseolorunk anmi, A., Oyedokun, A., Iweala, E. E. J., & Omoregbe, N. (2019). An estimate of the incidence of prostate cancer in Africa: A systematic review and me ta-analysis. PLOS ONE, 14(4), e0215588. |
| [9] | Szymańska, A., Procyk, D., Oleksyszyn, J., & Sieńczyk, M. (2019). Development and evaluation of an immunoglobulin Y-based ELISA for measuring prostate-specific antigen in human serum. Annals of Laboratory Medicine, 39(4), 373–380. |
| [10] | Murphy, G. P., Elgamal, A. A., Su, S. L., Bostwick, D. G., & Holmes, E. H. (1998). Measurement of serum prostate-specific membrane antigen, a new prognostic marker for prostate cancer. Urology, 51(5 Suppl. 1), 89–97. |
| [11] | Loeb, S., Vellekoop, A., Ahmed, H. U., Catto, J., Emberton, M., Nam, R., & Rosario, D. J. (2014). Systematic review of complications of prostate biopsy. European Urology, 66(6), 978–983. |
| [12] | Mottet, N., van den Bergh, R. C. N., Briers, E., et al. (2024). EAU guidelines on prostate cancer. European Association of Urology Guidelines. |
| [13] | Sung, H., Ferlay, J., Siegel, R. L., Laversanne, M., Soerjomataram, I., Jemal, A., & Bray, F. (2021). Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians, 71(3), 209–249. |
| [14] | Rebbeck, T. R. (2022). Prostate cancer genetics and disparities in risk and outcomes. Annual Review of Genomics and Human Genetics, 23, 357–381. |
| [15] | World Health Organisation. (2024). WHO report on the global tobacco epidemic 2024. World Health Organisation. |
| [16] | GBD 2021 Tobacco Collaborators. (2024). Spatial, temporal, and demographic patterns in the global burden of tobacco use, 1990–2021. The Lancet Public Health, 9(5), e343–e356. |
| [17] | Tobacco Collaborators. (2024). Spatial, temporal, and demographic patterns in the global burden of tobacco use, 1990–2021. The Lancet Public Health, 9(5), e343–e356. |
| [18] | Islami, F., Goding Sauer, A., Miller, K. D. (2022). Proportion and number of cancer cases attributable to potentially modifiable risk factors. CA: A Cancer Journal for Clinicians, 72(6), 553–578. |
| [19] | Hecht, S. S. (2012). Tobacco smoke carcinogens and the pathogenesis of smoking-related cancer. Nature Reviews Cancer, 12(9), 592–604. |
| [20] | Silver, D. A., Pellicer, I., Fair, W. R., Heston, W. D. W., & Cordon-Cardo, C. (2021). Prostate-specific membrane antigen expression in normal and malignant human tissues: Clinical implications. Clinical Cancer Research, 27(18), 5056–5064. |
| [21] | Platz, E. A., Rimm, E. B., Willett, W. C., Kantoff, P. W., Giovannucci, E., & Stampfer, M. J. (2001). Cigarette smoking, plasma antioxidants, and prostate-specific antigen concentrations. Cancer Epidemiology, Biomarkers & Prevention, 10(7), 729–733. |
| [22] | Kenfield, S. A., Stampfer, M. J., Chan, J. M., & Giovannucci, E. (2011). Smoking and prostate cancer survival and recurrence. JAMA, 305(24), 2548–2555. |
| [23] | Hofman, M. S., Lawrentschuk, N., Francis, R. J. (2020). Prostate-specific membrane antigen PET-CT in patients with high-risk prostate cancer before curative-intent surgery or radiotherapy (proPSMA): A prospective, randomised, multicentre study. The Lancet, 395(10231), 1208–1216. |
| [24] | Huncharek, M., Haddock, K. S., Reid, R., & Kupelnick, B. (2010). Smoking as a risk factor for prostate cancer: A meta-analysis of 24 prospective cohort studies. American Journal of Public Health, 100(4), 693–701. |
| [25] | Rodríguez, C., Freedland, S. J., Deka, A., (2019). Smoking intensity and prostate-specific antigen concentrations in adult men. Prostate Cancer and Prostatic Diseases, 22(2), 250–257. |
| [26] | Perera, M., Papa, N., Roberts, M., Williams, M., Udovicich, C., Vela, I., Christidis, D., Bolton, D., Hofman, M. S., & Murphy, D. G. (2020). Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer: Updated diagnostic accuracy. European Urology, 77(4), 403–417. |
APA Style
Josephine, O., Hellen, W. A., Holy, B. (2026). Diagnostic Relevance of Prostate-Specific Antigen and Membrane Antigen Levels in Male Smokers and Nonsmokers in Port Harcourt, Nigeria. International Journal of Clinical and Experimental Medical Sciences, 12(5), 96-102. https://doi.org/10.11648/j.ijcems.20261205.12
ACS Style
Josephine, O.; Hellen, W. A.; Holy, B. Diagnostic Relevance of Prostate-Specific Antigen and Membrane Antigen Levels in Male Smokers and Nonsmokers in Port Harcourt, Nigeria. Int. J. Clin. Exp. Med. Sci. 2026, 12(5), 96-102. doi: 10.11648/j.ijcems.20261205.12
@article{10.11648/j.ijcems.20261205.12,
author = {Osiagor Josephine and Wariboko Anthony Hellen and Brown Holy},
title = {Diagnostic Relevance of Prostate-Specific Antigen and Membrane Antigen Levels in Male Smokers and Nonsmokers in Port Harcourt, Nigeria},
journal = {International Journal of Clinical and Experimental Medical Sciences},
volume = {12},
number = {5},
pages = {96-102},
doi = {10.11648/j.ijcems.20261205.12},
url = {https://doi.org/10.11648/j.ijcems.20261205.12},
eprint = {https://article.sciencepublishinggroup.com/pdf/10.11648.j.ijcems.20261205.12},
abstract = {Prostate cancer remains a significant global public health concern, including in Nigeria, where increasing incidence and late- stage presentation have been reported in urban centres such as Port Harcourt. This study compared prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) levels among male smokers and non-smokers in Port Harcourt, Nigeria, to assess their diagnostic relevance and the influence of lifestyle factors. A comparative cross-sectional design was employed, involving 180 male participants aged 40–60 years: 90 smokers and 90 non-smokers recruited through convenience sampling. Data were collected using structured questionnaires covering demographic and lifestyle variables. We collected, processed, and analysed venous blood samples (5 mL) for PSA and PSMA levels using sandwich enzyme-linked immunosorbent assay (ELISA) techniques. Statistical analyses were performed using GraphPad Prism version 8.02. We compared groups using one-way ANOVA and post hoc tests, with statistical significance set at p < 0.05. We also performed receiver operating characteristic (ROC) curve analysis to evaluate diagnostic performance. The results showed that smokers had significantly higher mean PSA (4.48 ± 1.082 ng/mL) and PSMA (4.00 ± 1.628 ng/mL) levels than non- smokers (PSA: 1.98 ± 0.298 ng/mL; PSMA: 1.88 ± 0.145 ng/mL), with p- values of 0.0003 and < 0.0001, respectively. ROC analysis showed that PSMA had superior diagnostic performance (AUC = 0.766) than PSA (AUC = 0.634). Alcohol consumption was also significantly associated with elevated PSA and PSMA levels, whereas exercise had a significant but variable effect. Age influenced biomarker levels in specific groups, while smoking intensity and duration showed weak, non- significant correlations with both markers. In conclusion, smoking was associated with elevated prostate biomarkers, suggesting an increased risk of prostate dysfunction. PSMA showed greater diagnostic capability than PSA, suggesting it may be a more reliable biomarker for early detection. Integrating both biomarkers with lifestyle interventions may strengthen prostate cancer screening and prevention strategies.},
year = {2026}
}
TY - JOUR T1 - Diagnostic Relevance of Prostate-Specific Antigen and Membrane Antigen Levels in Male Smokers and Nonsmokers in Port Harcourt, Nigeria AU - Osiagor Josephine AU - Wariboko Anthony Hellen AU - Brown Holy Y1 - 2026/11/19 PY - 2026 N1 - https://doi.org/10.11648/j.ijcems.20261205.12 DO - 10.11648/j.ijcems.20261205.12 T2 - International Journal of Clinical and Experimental Medical Sciences JF - International Journal of Clinical and Experimental Medical Sciences JO - International Journal of Clinical and Experimental Medical Sciences SP - 96 EP - 102 PB - Science Publishing Group SN - 2469-8032 UR - https://doi.org/10.11648/j.ijcems.20261205.12 AB - Prostate cancer remains a significant global public health concern, including in Nigeria, where increasing incidence and late- stage presentation have been reported in urban centres such as Port Harcourt. This study compared prostate-specific antigen (PSA) and prostate-specific membrane antigen (PSMA) levels among male smokers and non-smokers in Port Harcourt, Nigeria, to assess their diagnostic relevance and the influence of lifestyle factors. A comparative cross-sectional design was employed, involving 180 male participants aged 40–60 years: 90 smokers and 90 non-smokers recruited through convenience sampling. Data were collected using structured questionnaires covering demographic and lifestyle variables. We collected, processed, and analysed venous blood samples (5 mL) for PSA and PSMA levels using sandwich enzyme-linked immunosorbent assay (ELISA) techniques. Statistical analyses were performed using GraphPad Prism version 8.02. We compared groups using one-way ANOVA and post hoc tests, with statistical significance set at p < 0.05. We also performed receiver operating characteristic (ROC) curve analysis to evaluate diagnostic performance. The results showed that smokers had significantly higher mean PSA (4.48 ± 1.082 ng/mL) and PSMA (4.00 ± 1.628 ng/mL) levels than non- smokers (PSA: 1.98 ± 0.298 ng/mL; PSMA: 1.88 ± 0.145 ng/mL), with p- values of 0.0003 and < 0.0001, respectively. ROC analysis showed that PSMA had superior diagnostic performance (AUC = 0.766) than PSA (AUC = 0.634). Alcohol consumption was also significantly associated with elevated PSA and PSMA levels, whereas exercise had a significant but variable effect. Age influenced biomarker levels in specific groups, while smoking intensity and duration showed weak, non- significant correlations with both markers. In conclusion, smoking was associated with elevated prostate biomarkers, suggesting an increased risk of prostate dysfunction. PSMA showed greater diagnostic capability than PSA, suggesting it may be a more reliable biomarker for early detection. Integrating both biomarkers with lifestyle interventions may strengthen prostate cancer screening and prevention strategies. VL - 12 IS - 5 ER -